Drug Profile
Efpegsomatropin - Hanmi Pharmaceutical
Alternative Names: HM-10560A; LAPS-hGH; LAPS-rhGHLatest Information Update: 30 Aug 2017
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Growth hormones; Hormonal replacements; Polyethylene glycols
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Somatotropin deficiency
Most Recent Events
- 30 Aug 2017 Phase-II development is ongoing in Somatotropin deficiency (Hanmi Pharmaceutical pipeline, August 2017)
- 13 Mar 2015 Phase-II clinical trials in Somatotropin deficiency in Ukraine, Serbia, Russia, Romania, India, Bulgaria and South Korea (SC) after October 2011 (EudraCT2011-001826-61)
- 06 Feb 2014 Hanmi Pharmaceutical completes enrolment in its phase II trial for Somatotropin deficiency in Hungary (NCT01822340)